Update on DCIS outcomes from the American Society of Breast Surgeons accelerated partial breast irradiation registry trial.
Update on DCIS outcomes from the American Society of Breast Surgeons accelerated partial breast irradiation registry trial.
复制标题
美国乳房外科医生学会的DCI结果加速了部分乳房辐照注册表试验。
DOI：
10.1245/s10434-010-1192-z
复制
发表时间：
2011-01
影响因子：
3.7
通讯作者：
Keisch M
中科院分区：
文献类型：
--
作者：
Jeruss JS;Kuerer HM;Beitsch PD;Vicini FA;Keisch M
自首次报告使用MammoSite加速部分乳腺照射（APBI）治疗导管原位癌（DCIS）以来，收集了额外的随访数据。我们假设通过MammoSite输送的APBI将继续具有良好的耐受性，与良好的美容结局相关，并且DCIS患者的复发风险较低。从2002年至2004年，194例DCIS患者入组了一项注册试验，以评估MammoSite。所有194例患者的随访数据均可用。中位随访时间为54.4个月; 63例患者至少随访5年。获得的数据包括患者、肿瘤和治疗相关因素以及复发率。在194例患者中，87例（45%）在乳房肿瘤切除术时放置了MammoSite; 107例（55%）在乳房肿瘤切除术后放置了该器械。在第一年的随访中，16名患者出现乳房感染，尽管器械放置方法与感染风险无关。此外，46名患者在乳房肿瘤切除术时发生了与施源器放置相关的血清肿（P = 0.001）。对于至少随访5年的患者，92%的患者具有良好的美容效果。有6例患者（3.1%）发生同侧乳腺复发，1例（0.5%）发生乳腺和腋窝复发，5年精确局部复发率为3.39%。在延长的随访期内，DCIS患者通过MammoSite输送的APBI仍然耐受良好。使用该器械可能使乳房肿瘤切除术成为可能，否则患者会因为标准放射治疗相关的障碍而选择乳房切除术。
Since the initial reports on use of MammoSite accelerated partial breast irradiation (APBI) for treatment of ductal carcinoma in situ (DCIS), additional follow-up data were collected. We hypothesized that APBI delivered via MammoSite would continue to be well tolerated, associated with a good cosmetic outcome, and carry a low risk for recurrence in patients with DCIS. From 2002–2004, 194 patients with DCIS were enrolled in a registry trial to assess the MammoSite. Follow-up data were available for all 194 patients. Median follow-up was 54.4 months; 63 patients had at least 5 years of follow-up. Data obtained included patient-, tumor-, and treatment-related factors, and recurrence incidence. Of the 194 patients, 87 (45%) had the MammoSite placed at lumpectomy; 107 patients (55%) had the device placed postlumpectomy. In the first year of followup, 16 patients developed a breast infection, though the method of device placement was not associated with infection risk. Also, 46 patients developed a seroma that was associated with applicator placement at the time of lumpectomy (P = 0.001). For patients with at least 5 years of follow-up, 92% had favorable cosmetic results. There were 6 patients (3.1%) who had an ipsilateral breast recurrence, with 1 (0.5%) experiencing recurrence in the breast and axilla, for a 5-year actuarial local recurrence rate of 3.39%. During an extended follow-up period, APBI delivered via MammoSite continued to be well tolerated for patients with DCIS. Use of this device may make lumpectomy possible for patients who would otherwise choose mastectomy because of barriers associated with standard radiation therapy.
登录
查看更多内容
影响因子：
6.2
作者：
Voti, L;Richardson, LC;Coebergh, JWW
通讯作者：
Coebergh, JWW
影响因子：
3.1
作者：
Emdin, Stefan O.;Granstrand, Bengt;Wallgren, Arne
通讯作者：
Wallgren, Arne
DOI：
10.1016/j.ijrobp.2005.12.045
发表时间：
2006-06-01
影响因子：
7
作者：
Evans, Suzanne B.;Kaufman, Seth A.;Wazer, David E.
通讯作者：
Wazer, David E.
影响因子：
6.2
作者：
Vicini, Frank;Beitsch, Peter D.;Lyden, Maureen
通讯作者：
Lyden, Maureen
影响因子：
2.1
作者：
Guenzi, Marina;Giannelli, Flavio;Corvo, Renzo
通讯作者：
Corvo, Renzo